ClinicalTrials.gg
Not yet recruitingNCT05891899Updated Dec 4, 2024

Belgian Antithrombin Deficiency Registry

An observational study in Antithrombin III Deficiency, sponsored by Universitair Ziekenhuis Brussel. Not yet recruiting at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Universitair Ziekenhuis Brussel · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Study summary

Inherited antithrombin deficiency is a rare autosomal dominant disorder that predisposes to the development of venous thromboembolism, even at young age.

Inherited AT deficiency is considered the most severe form of inherited thrombophilia, increasing up to 40 times the risk of venous thrombosis.

Our center has been performing research on antithrombin deficiency for several years. Therefore, it was decided to initiate a registry for patients with inherited antithrombin deficiency with the goal to gain more insight into what drives the development of a thrombotic event in patients with AT deficiency, both at the environmental level (lifestyle, management of risk situations, presence of additional thrombotic risk factors...) and at the genetic level.

Read the detailed description

Background:

Antithrombin (AT) is the most important physiological inhibitor of blood coagulation, targeting predominantly factor X and thrombin (Factor II). It is a serine protease inhibitor encoded by the SERPINC1 gene and is synthesized in the liver. Inherited antithrombin deficiency is a rare autosomal dominant disorder that predisposes to the development of venous thromboembolism (VTE), even at young age. We can distinguish two types of AT deficiency: quantitative (type I) and qualitative (type II) deficiencies. According to which function of the protein is affected, type II deficiencies are subdivided into Heparin Binding Site (HBS), Reactive Site (RS) or Pleiotropic Effect (multiple functions or conformational consequences) deficiencies.

Inherited AT deficiency is considered the most severe form of inherited thrombophilia, increasing up to 40 times the risk of venous thrombosis. Antithrombin deficiency is a rare monogenic autosomal dominant disorder although the exact prevalence of AT deficiency remains largely unknown, probably because of the wide clinical heterogeneity. More than 400 different genetic variants in SERPINC1 have been identified. Diagnosis of AT deficiency is done by functional assays that are based on the inhibition of target proteases (Factor Xa or Factor IIa) in the presence of heparin. While biochemical, structural, and molecular information about AT is ample, there is a limited knowledge about the natural history of this disorder. The risk of venous thrombosis in carriers of AT deficiency is well documented but there are many important issues concerning the natural history of AT deficiency that must be unraveled: First, there is a remarkable heterogeneous presentation of AT deficiency. Type I deficiency has been associated with poorer prognosis than type II, but no systematic genotype-phenotype correlations have been done. Moreover, as for any other thrombotic disorder, we could expect that additional factors may modulate the risk of thrombosis in AT deficiency, even for carriers of the same genetic defect.

Objective In this study, the investigators will retrospectively and prospectively collect data on all AT deficient patients diagnosed in or referred to our center for diagnostic work up. The data will be used to create a national registry of antithrombin deficient patients.

The data collected in this registry will allow to gain more insight into what drives the development of a thrombotic event in patients with AT deficiency, both at the environmental level (lifestyle, management of risk situations, presence of additional thrombotic risk factors...) and at the genetic level. Data on obstetric complications and use of anticoagulant drugs will also be collected.

The study will help to assess the thromboembolic risk linked to distinct mutations and different (sub)types of AT deficiency. The findings could help steering the therapeutic attitude and give clinicians the opportunity to propose a more individually, patient-based approach for anticoagulation.

Furthermore, the observations will form the basis for more fundamental research into the pathophysiology of thrombosis in antithrombin deficient patients.

The registry will enroll as many confirmed or suspected hereditary AT deficiency patients as possible; there is no cap on enrollment. The registry enrollment and follow-up periods are open-ended. The endpoints for patients with confirmed or suspected hereditary AT deficiency are death or withdrawal of consent.

02

Conditions studied

  • Antithrombin III Deficiency
03

In context

Lead sponsor

Universitair Ziekenhuis Brussel is the lead sponsor of 375 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with confirmed inherited antithrombin deficiency are eligible for enrollment

Eligibility criteria

Inclusion Criteria:

  • Patients with genetically confirmed antithrombin deficiency
  • Patients with phenotypic antithrombin deficiency in which the genetic defect has not been elucidated yet.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
25 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Antithrombin deficient patients

    patients with proven, inherited antithrombin deficiency

    Other: observation

Interventions

  • Otherobservation

    No interventions planned: treatment of patients at the discretion of the treating/responsible physician

06

What researchers measure

Primary outcomes

  1. Change in occurrence of thromboembolic events over time

    Inquiry on occurrence of thromboembolic event by means of questionnaire

    Time frame: Every 2 years for a period of 25 years or until death, whichever comes first

  2. Change in occurrence of arterial thrombotic events over time

    Inquiry on occurrence of arterial thrombotic event by means of questionnaire

    Time frame: Every 2 years for a period of 25 years or until death, whichever comes first

  3. Change in occurrence of obstetric complications over time

    Inquiry on occurrence of obstetric complications by means of questionnaire

    Time frame: Every 2 years for a period of 25 years or until death, whichever comes first

Secondary outcomes

  1. Change in disease-modifying factors: thrombotic risk factors

    collection of disease-modifying factors by means of questionnaire

    Time frame: Every 2 years for a period of 25 years or until death, whichever comes first

  2. Change in anticoagulant treatment

    collect data on use of anticoagulant treatment by means of questionnaire

    Time frame: Every 2 years for a period of 25 years or until death, whichever comes first

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for Dec 2030, 67 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2023
First posted
Jun 7, 2023
StartEst.
May 2025
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2060
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05891899
Responsible party
Christelle Orlando (Professor, Universitair Ziekenhuis Brussel) — Principal investigator
First posted
Jun 7, 2023
Start date
May 2025 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2060 (estimated)
Last update
Dec 4, 2024

Study contacts

Christelle Orlando, PhD
Contact
christelle.orlando@uzbrussel.be
0032 4763528
Christelle Orlando, PhD
principal investigator · Universitair Ziekenhuis Brussel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion